624 P. Pacher et al.
Randall MD, Alexander SP, Bennett T, Boyd EA, Fry JR, Gardiner SM, Kemp PA, McCul-
loch AI, Kendall DA (1996) An endogenous cannabinoid as an endothelium-derived
vasorelaxant. Biochem Biophys Res Commun 229:114–120
Randall MD, Harris D, Kendall DA, Ralevic V (2002) Cardiovascular effects of cannabinoids.
Pharmacol Ther 95:191–202
Ros J, Claria J, To-Figueras J, Planaguma A, Cejudo-Martin P, Fernandez-Varo G, Martin-
Ruiz R, Arroyo V, Rivera F, Rodes J, Jimenez W (2002) Endogenous cannabinoids: a new
system involved in the homeostasis of arterial pressure in experimental cirrhosis in the
rat. Gastroenterology 122:85–93
Rosenkrantz H, Braude M (1974) Acute, subacute and 23-day chronic marihuana inhalation
toxicities in the rat. Toxicol Appl Pharmacol 28:428–441
Sagan S, Venance L, Torrens Y, Cordier J, Glowinski J, Giaume C (1999) Anandamide
and WIN55,212–2 inhibit cyclic AMP-formation through G-protein-coupled receptors
distinct from CB1 cannabinoid receptors in cultured astrocytes. Eur J Neurosci 11:691–
699
Schlicker E, Timm J, Zentner J, Gothert M (1997) Cannabinoid CB1 receptor-mediated
inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn
Schmiedebergs Arch Pharmacol 356:583–589
Siqueira SW, Lapa AJ, Ribeiro do Valle J (1979) The triple effect induced by delta 9-tetra-
hydrocannabinol on the rat blood pressure. Eur J Pharmacol 58:351–357
Smith PJ, McQueen DS (2001) Anandamide induces cardiovascular and respiratory reflexes
via vasosensory nerves in the anaesthetized rat. Br J Pharmacol 134:655–663
Stein EA, Fuller SA, Edgemond WS, Campbell WB (1996) Physiological and behavioural
effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the
rat. Br J Pharmacol 119:107–114
Szabo B, Nordheim U, Niederhoffer N (2001) Effects of cannabinoids on sympathetic and
parasympathetic neuroeffector transmission in the rabbit heart. J Pharmacol Exp Ther
297:819–826
Szolcsányi J (2000) Are cannabinoids endogenous ligands for the VR1 capsaicin receptor?
Trends Pharmacol Sci 21:41–42
Ugdyzhekova DS, Bernatskaya NA, Stefano JB, Graier VF, Tam SW, Mekhoulam R (2001)
Endogenous cannabinoid anandamide increases heart resistance to arrhythmogenic
effects of epinephrine: role of CB(1) and CB(2) receptors. Bull Exp Biol Med 131:251–
253
Ugdyzhekova DS, Krylatov AV, Bernatskaya NA, Maslov LN, Mechoulam R, Pertwee RG
(2002) Activation of cannabinoid receptors decreases the area of ischemic myocardial
necrosis. Bull Exp Biol Med 133:125–126
Valk PJ, Delwel R (1998) The peripheral cannabinoid receptor, Cb2, in retrovirally-induced
leukemic transformation and normal hematopoiesis. Leuk Lymphoma 32:29–43
Varga K, Lake K, Martin BR, Kunos (1995) G Novel antagonist implicates the CB1 cannabi-
noid receptor in the hypotensive action of anandamide. Eur J Pharmacol 278:279–283
Varga K, Lake KD, Huangfu D, Guyenet PG, Kunos G (1996) Mechanism of the hypotensive
action of anandamide in anesthetized rats. Hypertension 28:682–686
Varga K, Wagner JA, Bridgen DT, Kunos G (1998) Platelet- and macrophage-derived endoge-
nous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12:1035–
1044
Varma DR, Goldbaum D (1975) Effect of delta9-tetrahydrocannabinol on experimental
hypertension in rats. J Pharm Pharmacol 27:790–791
VidrioH,Sanchez-SalvatoriMA,MedinaM(1996)Cardiovasculareffectsof(–)-11-OH-delta
8-tetrahydrocannabinol-dimethylheptyl in rats. J Cardiovasc Pharmacol 28:332–336
Vizi ES, Katona I, Freund TF (2001) Evidence for presynaptic cannabinoid CB(1) receptor-
mediated inhibition of noradrenaline release in the guinea pig lung. Eur J Pharmacol
431:237–244